Inventor · disambiguated record
Joseph Schlessinger
Also filed as: SCHLESSINGER JOSEPH · SCHLESSINGER JOSEPH P · SELA MICHAEL
51 granted patents·20 pending applications·806 citations·filing 1992–2023
98Inventor score
Top patents by PatentIndex Score
71 records- 0191US7129072B1Crystal of fibroblast growth factor receptor 1 in complex with fibroblast growth factorUNIV NEW YORK·Filed 2000·Granted Oct 31, 2006·49 cites·1 claims
- 0291US6217866B1Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing sameYEDA RES & DEV·Filed 1995·Granted Apr 17, 2001·310 cites·9 claims
- 0390US9540443B2Anti-kit antibodiesHADARI YARON·Filed 2012·Granted Jan 10, 2017·21 cites·41 claims
- 0489US10793639B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Oct 6, 2020·3 cites·22 claims
- 0589US10189907B2Polynucleotides encoding anti-KIT antibodiesCELLDEX THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·6 cites·34 claims
- 0685US2024141063A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0783US7872016B2Method for treating skeletal disorders resulting from FGFR malfunctionUNIV YALE·Filed 2005·Granted Jan 18, 2011·13 cites·8 claims
- 0880US5783568AMethods for treating cancer and other cell proliferative diseasesSUGEN INC·Filed 1994·Granted Jul 21, 1998·67 cites·9 claims
- 0979US5863888AHuman Bek Fibroblast growth factor receptorRHONE POULENC RORER PHARMA·Filed 1995·Granted Jan 26, 1999·37 cites·9 claims
- 1076US5434064AExpression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target proteinsUNIV NEW YORK·Filed 1992·Granted Jul 18, 1995·34 cites·8 claims
- 1173US11884699B2Anti-KIT antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·20 claims
- 1273US6344546B1Fibroblast growth factor receptorsRHONE POULENC RORER INC·Filed 1994·Granted Feb 5, 2002·40 cites·5 claims
- 1372US5837815APYK2 related polypeptide productsSUGEN INC·Filed 1995·Granted Nov 17, 1998·30 cites·8 claims
- 1471US5942428ACrystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinasesSUGEN INC·Filed 1996·Granted Aug 24, 1999·35 cites·4 claims
- 1570US6803452B2RPTP-β antibodiesUNIV NEW YORK·Filed 2001·Granted Oct 12, 2004·1 cites·3 claims
- 1669US6682921B1Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinasesUNIV NEW YORK·Filed 2000·Granted Jan 27, 2004·1 cites·4 claims
- 1768US11365228B2Mutant FGF21 polypeptide compositionsUNIV YALE·Filed 2018·Granted Jun 21, 2022·0 cites·5 claims
- 1862US5856162AReceptor-type phosphotyrosine phosphatase-κUNIV NEW YORK MED CT·Filed 1995·Granted Jan 5, 1999·10 cites·10 claims
- 1960US6045797ATreatment or diagnosis of diseases or conditions associated with a BLM domainUNIV NEW YORK MED CT·Filed 1997·Granted Apr 4, 2000·15 cites·8 claims
- 2060US5538886AReceptor-type phosphotyrosine phosphatase-alphaUNIV NEW YORK·Filed 1993·Granted Jul 23, 1996·19 cites·13 claims
- 2159US12110278B2Selective JAK2 pseudokinase ligands and methods of useUNIV YALE·Filed 2021·Granted Oct 8, 2024·0 cites·21 claims
- 2259US5861266ATreatment of diabetes mellitus and insulin receptor signal transductionUNIV NEW YORK·Filed 1994·Granted Jan 19, 1999·23 cites·26 claims
- 2358US5858686AMethods for detecting tyrosine kinase-binding target proteins and identifying substances that affect SH2 phosphorylated ligand regulatory systemsUNIV NEW YORK·Filed 1995·Granted Jan 12, 1999·8 cites·18 claims
- 2458US2025228918A1Methods of controlling body weight and/or energy expenditureUNIV YALE·Filed 2023·Application pending·0 cites
- 2557US2024034762A1Compositions and Methods For Inhibiting FGF23 ActivityUNIV YALE·Filed 2021·Application pending·0 cites
- 2657US2003092079A1Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactionsNEW YORK UNIVERSITY DUKE UNIVE·Filed 2002·Application pending·0 cites
- 2755US7314620B2Methods for diagnosis and treatment of PH domain signal transduction disordersUNIV NEW YORK·Filed 2003·Granted Jan 1, 2008·0 cites·6 claims
- 2855US2003091551A1Treatment of diabetes mellitus and insulin receptor signal transductionNEW YORK UNIVERSITY MAX PLANCK·Filed 2002·Application pending·0 cites
- 2954US6576442B1rdgB proteins and related products and methodsSUGEN INC·Filed 2000·Granted Jun 10, 2003·0 cites·13 claims
- 3054US5888794AReceptor-type phosphotyrosine phosphatase-alphaUNIV NEW YORK·Filed 1995·Granted Mar 30, 1999·8 cites·9 claims
- 3154US2005032689A1Methods for treatment or diagnosis of disease or disorders associated with an APB domainUNIV NEW YORK·Filed 2003·Application pending·0 cites
- 3253US2019151351A1Regulators of anaplastic lymphoma kinase and uses thereofCELLDEX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3351US7108994B2Receptor-type phosphotyrosine phosphatase-alphaUNIV NEW YORK·Filed 2004·Granted Sep 19, 2006·0 cites·1 claims
- 3451US7056508B2Receptor-type phosphotyrosine phosphatase-kappa antibodiesMAX PLANCK GES FORGERUNG DER W·Filed 2001·Granted Jun 6, 2006·0 cites·32 claims
- 3551US2008114081A1Methods for diagnosis and treatment of PH domain signal transduction disordersUNIV NEW YORK·Filed 2007·Application pending·0 cites
- 3650US5837524APYK2 related polynucleotide productsSUGEN INC·Filed 1994·Granted Nov 17, 1998·11 cites·25 claims
- 3750US2002022023A1Treatment of diabetes mellitus and insulin receptor signal transductionFiled 2001·Application pending·0 cites
- 3849US5889150AExpression-cloning method for identifying target proteins for eukaryotic tyrosine kinases and novel target protiensUNIV NEW YORK MED CT·Filed 1994·Granted Mar 30, 1999·7 cites·14 claims
- 3949US2004185547A1Crystals of the tyrosine kinase domain of non-insulin receptor tyrosine kinasesSUGEN INC·Filed 2004·Application pending·0 cites
- 4048US2004005648A1PYK2 related products and methodsSUGEN INC·Filed 2003·Application pending·0 cites
- 4147US5846800ANucleic acid molecules encoding a novel receptor-type protein tyrosine phosphatase-σUNIV NEW YORK·Filed 1996·Granted Dec 8, 1998·5 cites·18 claims
- 4246US2003119067A1PYK2 related products and methodsSUGEN INC·Filed 2002·Application pending·0 cites
- 4345US5604094AReceptor-type phosphotyrosine phosphatase-βUNIV NEW YORK·Filed 1993·Granted Feb 18, 1997·5 cites·12 claims
- 4445US2004259158A1PYK2 and inflammationSUGEN INC·Filed 2004·Application pending·0 cites
- 4544US7135320B2Adaptor protein FRS2 and related products and methodsUNIV NEW YORK·Filed 2000·Granted Nov 14, 2006·0 cites·7 claims
- 4643US5618691ARecombinant DNA encoding a eukaryotic tyrosine kinase target proteinUNIV NEW YORK·Filed 1993·Granted Apr 8, 1997·4 cites·28 claims
- 4743US2017100428A1Regulators of anaplastic lymphoma kinase and uses thereofKOLLTAN PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4842US6160090AReceptor protein tyrosine phosphatasesUNIV NEW YORK·Filed 1993·Granted Dec 12, 2000·7 cites·15 claims
- 4939US6682905B1Receptor-type phosphotyrosine phosphatase-alphaUNIV NEW YORK·Filed 1999·Granted Jan 27, 2004·3 cites·10 claims
- 5039US5863755ANucleic acid encoding novel receptor-type phosphotyrosine phosphatase-κMAX PLANCK GESSELLSCHAFT·Filed 1993·Granted Jan 26, 1999·5 cites·19 claims
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Joseph Schlessinger files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →